Fujifilm speeds production of potential COVID-19 therapy Avigan

speedometer (pixabay)
Fujifilm will work with the Japanese government to pursue foreign exports of COVID-19 hopeful Avigan. (Pixabay)

After researchers targeted its influenza antiviral Avigan as a possible COVID-19 therapy, Japanese drugmaker Fujifilm said it was ready to scale up production to meet skyrocketing national demand. Now, with its foot on the gas pedal, Fujifilm hopes to make hundreds of thousands of regimens available in the coming months.

Fujifilm is expanding manufacturing capacity at its Toyama facility to speed production of flu antiviral drug Avigan, which has been targeted as a possible therapy for COVID-19, the drugmaker said Wednesday. 

The company has also "established strategic partnerships with domestic and overseas companies" to source raw materials for Avigan and added capacity at its Wako Pure Chemical Co. facility to produce the drug's active pharmaceutical ingredients, Fujifilm said in a release.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

With its supercharged production in place, Fujifilm is hoping to make 100,000 treatment courses of Avigan available by July––3.5 times its supply in March––and a total of 300,000 courses ready by September. The Japanese government will set aside 2 million treatment courses for its national stockpile, Fujifilm said, and the drugmaker is in discussions with foreign governments to provide additional supply. 

RELATED: Fujifilm ramps up production of flu drug Avigan as possible COVID-19 treatment

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.